Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Emergent BioSolutions excels in Q3, poised for growth opportunities

Emergent BioSolutions delivered a strong Q3 performance, showcasing financial resilience, operational excellence, and strategic advancements across key business segments.
While facing challenges in pricing dynamics and revenue mix, the company's focus on growth opportunities, compliance, and leadership appointments positions them for sustained success.
With a solid financial foundation, improved guidance, and a strategic roadmap for growth, Emergent is well-equipped to navigate challenges, capitalize on opportunities, and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DENVER--(BUSINESS WIRE)--Shuamn, Glenn & Stecker investigates Emergent BioSolutions, Inc. (NYSE: EBS).

Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.

Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.

Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence

Emergent BioSolutions Inc (NYSE: EBS) has signed a five-year agreement with Providence Therapeutics valued at about $90 million to develop and manufacture its COVID-19 vaccine candidate. Emergent will produce drug substances for Providence's vaccine candidate, PTX-COVID19-B, and provide services for finished products at its Winnipeg facility in Canada.

Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate

GAITHERSBURG, Md. and CALGARY, Alberta, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) and Providence Therapeutics today announced they have entered into a five-year contract development and manufacturing (CDMO) services agreement spanning Emergent's integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providence's COVID-19 messenger RNA (mRNA) vaccine development. In 2022, Emergent will manufacture tens of millions of doses of PTX-COVID19-B drug product, as well as batches of PTX-COVID19-B formulated bulk drug substance with the potential to yield hundreds of millions more doses, for global populations in need of pandemic relief.

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Alamos Gold

AppFolio

CDK Global

Campbell Soup

Kinross Gold

Perrigo

United States Cellular

There's plenty of solid opportunities out there, but these are stocks to sell. Here's why you should avoid each of these eight companies now.

8 F-Rated Stocks to Sell in September

EBS is currently being sued for a manufacturing error involving the mixing of ingredients, which may result in the loss of its COVID-19-related transactions.

Emergent BioSolutions: Positive Outlook Despite Current Lawsuit

Emergent BioSolutions Inc (NYSE: EBS) has announced the initiation of a Phase 3 trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy. Related:   Emergent BioSolutions' Plasma-Based Therapy Candidate Flunks COVID-19 Study.

Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment

GAITHERSBURG, Md., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy as a potential outpatient treatment for patients with coronavirus disease (COVID-19) that are at high risk of progression to severe disease, including adults 55 and older and those 18 and older who are immunocompromised.

Emergent BioSolutions' COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19

Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations.

Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit

Drug manufacturer Emergent BioSolutions Inc on Friday said it has received inquiries and subpoenas from a swathe of U.S. authorities related to its abilities to manufacture COVID-19 bulk drug substance.

U.S. authorities probing Emergent BioSolutions over COVID-19 vaccine issues -filing

Emergent Biosolutions' (EBS) CEO Bob Kramer on Q2 2021 Results - Earnings Call Transcript

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -81.77% and -4.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Lags Q2 Earnings and Revenue Estimates

GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2021.

Emergent BioSolutions Reports Financial Results For Second Quarter 2021

Emergent BioSolutions Inc (NYSE: EBS) will resume production of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated. The development comes after J&J last week slashed the 2021 production target of its single-dose vaccine to between 500 million and 600 million doses from its original goal to produce 1 billion shots.

Emergent BioSolutions Stock Higher As COVID-19 Vaccine Production To Resume At Baltimore Plant

GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent's Bayview manufacturing facility to resume production of Johnson & Johnson's (J&J) Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent's quality enhancement plan.

Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

GAITHERSBURG, Md., July 26, 2021 (GLOBE NEWSWIRE) --  An alliance of national nonprofit organizations comprised of Community Anti-Drug Coalitions of America (CADCA), Mothers Against Prescription Drug Abuse (MAPDA), SAFE Project, and Shatterproof, sponsored by Emergent BioSolutions Inc., (NYSE:EBS) today announced the launch of a new public awareness campaign, Reverse the Silence, which features television and radio spots that educate and help support people who may be at risk or know someone at risk of an opioid overdose.

Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use

Aerojet Rocketdyne Holdings

AstraZeneca

Jacobs Solutions Inc

Leidos Hld

Lockheed Martin

Moderna

Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal government.

These Companies Have Seen Large Returns From 2020 Government Investment

GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021.

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021

Emergent BioSolutions shareholders have brought a wave of lawsuits against the company related to its work on the Johnson & Johnson vaccine at its facility in the Bayview neighborhood of Baltimore.

Emergent BioSolutions Faces Lawsuits Related to Vaccine Troubles

Yes, but it probably won't be an easy path.

Can Emergent BioSolutions Recover From Its Recent Blunders?

New York, New York--(Newsfile Corp. - June 23, 2021) - Faruqi & Faruqi, LLP, a leading minority and Woman-owned national securities law firm, is investigating potential misconduct at Emergent BioSolutions Inc. ("Emergent BioSolutions" or the "Company") (NYSE: EBS).The investigation focuses on whether the Company's Board of Directors and/or officers breached their fiduciary duties. Request more information now by clicking here: www.faruqilaw.com/EBS. There is no cost or obligation to you.Take ActionIf you currently own...

Faruqi & Faruqi, LLP is Investigating Emergent BioSolutions (EBS) on Behalf of its Shareholders

New York, New York--(Newsfile Corp. - June 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between April 24, 2020 and April 16, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 21, 2021 - EBS

New York, New York--(Newsfile Corp. - June 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the "Class Period"), of the important June 21, 2021 lead plaintiff deadline.SO WHAT: If you purchased Emergent securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

Final Deadline Today: Rosen, Global Investor Counsel, Reminds Emergent BioSolutions Inc. Investors with Losses Over $100K of the Updated June 21 Deadline in Securities Class Action Due to the Recently Declared Federal Court Holiday - EBS

Los Angeles, California--(Newsfile Corp. - June 21, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 24, 2020 and April 16, 2021,...

FINAL DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - June 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the "Class Period"), of the important June 21, 2021 lead plaintiff deadline.SO WHAT: If you purchased Emergent securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

Final Deadline Monday: Rosen, A Top Ranked Law Firm, Reminds Emergent BioSolutions Inc. Investors with Losses Over $100K of the Updated June 21 Deadline in Securities Class Action Due to the Recently Declared Federal Court Holiday - EBS

News for Emergent BioSolutions Stock (EBS)